Enzon 3Q Revenues: $45.9 million (+4%) 3Q Earnings: $2.2 million (loss of $5.8 million 3Q2005)* Comments: Sales from the products segment were flat at $25.3 million. Sales of Oncaspar were up 28% to $7.4 million and sales of Adagen were up 16% to $6.9 million. Sales of Abelcet in the U.S. and Canada were $9 million, down 19% and sales of Depocytwere down 14% to $2 million. Contract manufacturing revenues were $1.9 million for the quarter as compared to $3.4 million 3Q2005. R&D e...